In focusing on medical aid in dying solely as an end, we’ve missed out on the life that was lived,” writes physician Sai ...
Kennedy and Oz say Medicaid isn't being cut. But state Medicaid directors say new policies are likely to cause many people to ...
Today, controversy over a regulator’s decision on AI scribes. Plus, a little more detail on Dexcom’s FDA pilot and an ...
A study of New York’s court-ordered care for people with serious mental health conditions adds to the research on this type ...
Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug ...
It is no longer possible to ask the FDA to keep pace with software development by doing the same reviews faster,” writes Dana ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Allison covers what hot startups are ...
The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to ...
Medicare is removing flexibilities that have allowed "breakthrough" medical devices to leapfrog qualifications for extra ...
Two people have died in the cyclospora outbreak in Michigan in the first confirmed deaths in the U.S. related to the ...
Six weeks after STAT reported that Eli Lilly granted a single 79-year-old patient special access to retatrutide, an ...
A White House proposal to subject research grants to political scrutiny meets at least a temporary roadblock in the Senate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results